Objective-Subendothelial retention of proatherogenic lipoproteins by proteoglycans is critical in atherosclerosis. The aim of this study was to characterize the recognition and antiatherogenic properties of a chimeric monoclonal antibody (mAb) that reacts with sulfated molecules. Methods and Results-chP3R99 mAb recognized sulfated glycosaminoglycans, mainly chondroitin sulfate (CS), by ELISA. This mAb blocked Ϸ70% of low-density lipoprotein (LDL)-CS association and Ϸ80% of LDL oxidation in vitro, and when intravenously injected to Sprague-Dawley rats (nϭ6, 1 mg/animal), it inhibited LDL (4 mg/kg intraperitoneally, 1 hour later) retention and oxidation in the artery wall. Moreover, subcutaneous immunization of New Zealand White rabbits (nϭ19) with chP3R99 mAb (100 g, 3 doses at weekly intervals) prevented Lipofundin-induced atherosclerosis (2 mL/kg, 8 days) with a 22-fold reduction in the intima-media ratio (PϽ0.01). Histopathologic and ultrastructural studies showed no intimal alterations or slight thickening, with preserved junctions between endothelial cells and scarce collagen fibers and glycosaminoglycans. In addition, immunization with chP3R99 mAb suppressed macrophage infiltration in aorta and preserved redox status. The atheroprotective effect was associated with the induction of anti-CS antibodies in chP3R99-immunized rabbits, capable of blocking CS-LDL binding and LDL oxidation. Conclusion-These results support the use of anti-sulfated glycosaminoglycan antibody-based immunotherapy as a potential tool to prevent atherosclerosis. (Arterioscler Thromb Vasc Biol. 2012;32:595-604.) (M.N.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
A therosclerosis is the underlying pathology of most cardiovascular events, and it is the main cause of morbidity and mortality in developed countries. 1 In this chronic inflammatory disease, the subendothelial retention of apolipoprotein B (apoB)-containing lipoproteins in the artery wall is the critical initiating step according to the "response-toretention" hypothesis. [2] [3] Proteoglycans (PGs), mainly those made up of chondroitin sulfate (CS) chains, are the most prominent components of the extracellular matrix (ECM) involved in atherogenesis. 4, 5 This process is mediated by electrostatic interactions between glycosaminoglycan (GAG) chains and basic residues present in apoB-containing lipoproteins, thereby increasing susceptibility to oxidation. 4 -7 Oxidized low-density lipoproteins (oxLDLs) are internalized by macrophages through cell surface scavenger receptors, leading to foam cell formation. 8, 9 Macrophage cell surface PGs are also involved in oxLDL binding and contribute to their uptake and catabolism. 8, 10 Furthermore, lesion progression is characterized by CSPG accumulation at atherosclerosis-prone sites, side chain elongation, and increasing in sulfation degree. 11, 12 Up to now, therapeutic approaches to atherosclerosis have been largely limited to risk factors, targeting mainly hypercholesterolemia and hypertension. 12 However, the maximum efficacy of these strategies in different clinical trials has been 30% to 40%. 13 Different immunotherapeutic approaches have been evaluated in preclinical and clinical studies not only with the purpose of interfering with lipoprotein metabolism 14 but also of modulating specific immune responses that play key roles in the development of the inflammatory process involved in the pathogenesis of the disease. 15 In contrast, therapies based on vessel wall targets, especially those directed to prevent the subendothelial retention of atherogenic lipoproteins, have been much less explored. Endostatin, a fragment of collagen type XVIII released by proteolysis, was shown to interfere with lipoprotein retention in subendothelial matrix. 16 In addition, immunization with apoB100derived peptides containing 1 of the PG binding sites has been considered a promising strategy to block LDL retention in vivo. 17 Our therapeutic strategy, not previously explored, is the use of antibodies that through their recognition of proatherogenic GAGs interfere with LDL retention and are also capable of inducing autologous antibodies with similar properties in the immunized animals, acting as idiotypic vaccines. 18 We have previously demonstrated the induction of idiotypic cascades by an idiotypic vaccine in cancer patients. 19 -21 P3 is a murine monoclonal antibody (mAb) that recognizes several N-glycolylated gangliosides and sulfatides. 22 P3 mAb has the unusual property of generating a strong anti-idiotypic response when administered in a syngenic animal model, even in the absence of adjuvants or carrier proteins. 23 The chimeric mouse/human IgG1 variant of P3 mAb (chP3) maintained the specificity and idiotypic immunogenicity of the murine antibody. 24 Mutation of arginine residues at heavy chain complementarity determining region (H-CDR1 and 3) showed that they were crucial for P3 mAb antigen binding. 25 Recently, our group obtained a chP3 mutant with an additional arginine in position 99 of H-CDR3 (Kabat numbering; chP3R99), displaying higher reactivity with antigens and more dramatically with sulfatides. 26 The purpose of this study was to characterize the reactivity of chP3R99 mAb to GAGs, its effect in foam cell formation, and its capacity to inhibit LDL retention and oxidation in the artery wall. Moreover, we investigated the potential of immunization with chP3R99 mAb to induce anti-GAG antibodies and their impact in the development of atherosclerosis in rabbits.
Materials and Methods
chP3R99 mAb reactivity to different GAGs was evaluated by ELISA. The effect of chP3R99 mAb in foam cell formation was studied through its capacity to block oxLDL uptake by J774A.1 macrophage cells. Inhibition of LDL-CS binding by chP3R99 mAb, rabbit sera, and IgG from immunized rabbits was performed by competitive ELISA, and their capacity to prevent LDL oxidation in vitro was analyzed by monitoring malondialdehyde (MDA) formation. The capacity to block LDL retention and oxidation in the artery wall was evaluated in rats. To assess the antiatherogenic effect of chP3R99 mAb in vivo, New Zealand White rabbits were subcutaneously immunized with low doses of the mAb before daily administration of Lipofundin medium-chain triglycerides/shortchain triglycerides 20% (referred to as Lipofundin) for 8 days. Aortic arches were used for histopathology, ultrastructural, and redox evaluation. Immunohistochemical studies were performed for detection of macrophages and CD4 and CD8 lymphocytes in rabbit aortas. Serum lipid parameters were measured using Randox Ltd kits, and redox variables were spectrophotometrically determined in supernatants from homogenates of rabbit aortas. Induction of anti-GAG antibodies by chP3R99 mAb immunization was evaluated in rabbit sera by ELISA. A full description of the methods is given in the online-only Data Supplement.
Results chP3R99 mAb Reacted With Sulfated GAGs and Human Atherosclerotic Lesions
It was previously demonstrated that P3 mAb reacts with sulfatides through electrostatic interactions. 22 Because of the relevance of sulfation degree of arterial GAG chains in atherogenesis, 11 we evaluated the reactivity of chP3R99 mAb to these molecules. The antibody recognized heparin ( Figure  1A ), heparan sulfate ( Figure 1B ), and dermatan sulfate (DS) ( Figure 1D ) in a similar way, despite differences in sulfation pattern among these GAGs. Interestingly, the highest reactivity was observed for CS ( Figure 1C ). It also recognized human aortic PGs ( Figure 1F ) and decorin (not shown), made up of CS and DS GAGs. In contrast, chP3R99 mAb showed a lower reactivity with hyaluronic acid ( Figure 1E ), a nonsulfate-containing GAG. Besides, chP3R99 mAb recognized GAGs with higher affinity than the parental chP3 mAb, whereas no reactivity was detected for chP3S98 mAb, a mutated variant of P3 where the arginine residue at position 98 of H-CDR3 was replaced by serine. 25 In addition, chP3R99 showed low or no reactivity with fibronectin, laminin, collagen I, fibrinogen,LDL,oxLDL,1-palmitoyl-2(5Ј-oxo-valeroyl)-sn-glycero-3-phosphorylcholine, or 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine ( Figure I 
chP3R99 mAb Did Not Inhibit oxLDL Uptake by J774A.1 Cells
The significant amounts of cell surface PGs on J774A.1 cell membrane, and their involvement in oxLDL uptake and catabolism, 10 prompted us to study the possible effect of chP3R99 mAb in foam cell formation. First, binding to J774A.1 cells was determined by flow cytometry. More than 95% of the cells were recognized by chP3R99, whereas no reactivity was observed with chP3S98 mAb ( Figure IIIA 
chP3R99 mAb Inhibited LDL Retention and Oxidation
To evaluate the ability of chP3R99 to inhibit LDL-CS association in vitro, CS-coated immunoassay plates were coincubated with b-LDL and different amounts of the chimeric antibodies. chP3R99 mAb inhibited the binding of b-LDL to CS in a dose-dependent manner, reaching Ϸ70% inhibition with 80 g/mL of this mAb. At this concentration, chP3 mAb inhibited only 36%. In contrast, chP3S98 had no effect, whereas the maximum inhibition was obtained when unlabeled LDL was used as competitor ( Figure 2A ).
To evaluate whether the capacity to block binding of LDL to CS would have further implications in LDL oxidation, we performed an LDL oxidation inhibition assay in vitro. In the presence of CS, LDL was Ϸ2-fold more susceptible to undergoing Cu 2ϩ oxidation. chP3R99 mAb inhibited Ϸ75% of MDA formation, whereas no inhibition was detected for hR3 mAb, used as isotype-matched control ( Figure 2B ).
Further exploration of the chP3R99 mAb effect on LDL retention and oxidation in the artery wall was done in rats. By means of CBLDL3 and EO6 mAbs, LDL and oxLDL were detected in the arterial endothelium, intima, and media 24 hours after intraperitoneal injection of LDL in rats that received phosphate-buffered saline (PBS) or the isotypematched control hR3 mAb ( Figure 2C-2E ). In contrast, intravenous administration of chP3R99 mAb 1 hour before LDL resulted in a clear reduction in arterial retention and oxidation of these particles. Accordingly, chP3R99 mAb was detected in rat artery wall, suggesting an inhibitory effect on LDL retention and subsequent oxidative modifications 
chP3R99 mAb Prevented Atherosclerosis in New Zealand White Rabbits
To assess the antiatherogenic effect of chP3R99 mAb in vivo, New Zealand White rabbits were subcutaneously injected with low doses of the mAb before Lipofundin infusion. Macroscopic and microscopic examination of organs did not show any relevant disease or abnormalities. The body weight did not vary significantly in any experimental group on Lipofundin administration. Microscopic analysis of aortic arch sections from control rabbits showed neither intimal thickening nor distortion in the vascular architecture (data not shown). Meanwhile, intravenous infusion of Lipofundin induced aortic atherosclerotic lesions in all PBS-receiving rabbits and those previously injected with hR3 ( Figure 3 ) or chP3 (data not shown) mAbs. Lesions were characterized by intimal thickening with accumulation of abundant subendo- ELISA plates were coated with 10 g/mL CS. Biotin-conjugated LDL (2.5 g/mL) was coincubated with different concentrations of the chimeric mAbs. B, Inhibition of LDL oxidation in vitro. LDL oxidation was measured as nmol/L malondialdehyde (MDA) produced by preincubating CS (100 g/mL) with mAbs (1 mg/mL) followed by the addition of LDL (25 g/mL) and CuSO 4 (10 mol/L). Percentages of inhibition were calculated relative to the maximum of LDL oxidation dependent on the binding to CS. C, Immunohistochemical staining of aortic sections from rats treated with 1 mg of chimeric antibodies before intraperitoneal injection of LDL (4 mg/kg). LDL and oxidized LDL (oxLDL) were detected with CBLDL3 and EO6 mAbs (10 g/mL), respectively. Accumulation of chP3R99 mAb in the artery wall was detected with a peroxidase-conjugated goat anti-human IgG antibody (magnification ϫ20). Scale barsϭ100 m. PBS indicates phosphate-buffered saline. D and E show the percentages of CBLDL3 ϩ and EO6 ϩ areas with respect to total area. Data are meanϮSEM.
thelial extracellular material. Alcian Blue staining revealed increased quantities of GAGs in the artery wall ( Figure 3A and 3D). We also observed media-to-intima migration of smooth muscle cells (SMCs) and abundant collagen fibers ( Figure 3B and 3E). Conversely, the immunization with chP3R99 mAb prevented atheromatous lesions in 8 rabbits, whereas minor lesions were observed in the 6 remaining animals. In the latter, only slight thickening of the intima was observed with scarce quantities of GAGs and collagen fibers. SMCs showed spindle-like morphology and were longitudinally arranged ( Figure 3G Immunohistochemical studies performed in fresh frozen sections of aortas showed a strong RAM-11 staining in the aortic artery wall and endothelium of PBS-receiving rabbits and those immunized with hR3 before Lipofundin infusion. In contrast, no macrophage infiltration was detected in the aorta sections from rabbits immunized with chP3R99 or chP3R99-LALA mAbs (Figure 3C-3I; Figure IV in the online-only Data Supplement). No CD4 or CD8 lymphocyte infiltrates and no human immunoglobulins were detected in any sample in the atherosclerotic plaques at the time of euthanization (data not shown).
Morphometric analyses of aortic arches showed that Lipofundin produced a significant increase in intima-to-media ratio (1.750Ϯ0.340) compared with control rabbits (0.015Ϯ0.004), PϽ0.001. Immunization with chP3R99 led to a 22-fold reduction in intima-to-media ratio (0.08Ϯ0.05) compared with Lipofundin group (PϽ0.001).
Further transmission electron microscopy ultrastructural examination confirmed the results observed by light microscopy. No alterations in the aortic artery wall of control rabbits were observed, characterized by a thin intima layer with SMCs immediately underlying the endothelium ( Figure 4A -4C). In contrast, Lipofundin caused striking alterations in the endothelium of animals that received PBS, with loss of intercellular junctions ( Figure 4D ). Additionally, the subendothelial space was thickened, with accumulation of basement membrane-like material, high amounts of collagen fibers (in both transverse and longitudinal dispositions), and The mAbs were subcutaneously injected (100 g in phosphate-buffered saline [PBS], 3 doses at weekly intervals) before atherosclerosis induction by intravenous administration of Lipofundin medium-chain triglycerides/short chain triglycerides 20% (2 mL/kg) for 8 days or PBS in control groups. Alcian blue, Masson trichromic, and RAM-11 stainings (magnification ϫ20) showed intimal thickening with distortion in smooth muscle cell arrangement and accumulation of glycosaminoglycans (GAGs) (A) and collagen (B), and macrophage infiltration (C) in aortas from Lipofundin-treated rabbits and those receiving hR3 isotype-matched control (D-F). Only minor lesions were observed in chP3R99-treated rabbits with scarce quantities of GAGs (G) and collagen fibers (H) and no macrophage infiltration (I). Scale barsϭ50 m.
abundant extracellular lipid vacuoles ( Figure 4E ). We also detected high number of foam cells derived both from macrophages and SMCs ( Figure 4F ). Similar characteristics were observed in hR3-receiving rabbits, with SMC dedifferentiation to ECM-producing myofibroblasts ( Figure 4G -I), and chP3-treated rabbits (data not shown). In contrast, no endothelial damage was detected in any of the chP3R99-receiving animals ( Figure 4J ). Subendothelial space from rabbits that developed atherosclerotic lesions in this group was characterized by ECM accumulation with scarce collagen fibers ( Figure 4K and 4L ).
Histopathologic and ultrastructural results together showed that Lipofundin-treated rabbits manifested human-like type III or IV atherosclerotic lesions, chP3-or hR3-receiving animals were classified as type III lesions, and chP3R99immunized animals showed no lesions (4 of 9) or type I atherosclerotic lesions (5 of 9).
chP3R99 Did Not Modulate Serum Lipids but Partially Preserved Redox Status
Before Lipofundin infusion, serum lipid levels and redox biomarkers were similar in all experimental groups, and no significant changes occurred in the control rabbits throughout the study (data not shown). Serum total cholesterol, LDL cholesterol, and high-density lipoprotein cholesterol levels were similar in all Lipofundin-receiving animals and significantly higher than those of the normolipemic control group (PϽ0.05) (Table) . Triglyceride levels also increased on Lipofundin infusion, with no effect of any of the antibodies. Thus, chP3R99 mAb administration did not avoid the increase in blood cholesterol and triglyceride levels caused by Lipofundin.
The Table shows the effect of immunization with chP3R99 mAb on biomolecule oxidation in atherosclerotic plaque homogenate. MDA, peroxidation potential, and advanced oxidation protein product (AOPP) concentrations were measured as surrogate markers of lipid and protein damage, revealing an increase in these variables in Lipofundin and hR3 control groups. Interestingly, chP3R99 mAb protected against increase of MDA, peroxidation potential, and partially AOPP levels (PϽ0.05). Also, chP3 mAb had a partial effect on AOPP levels and peroxidation potential (PϽ0.05). Furthermore, the increase in superoxide dismutase activity was lower in chP3R99-treated rabbits (PϽ0.05) compared with the remaining groups, although hR3-and chP3-receiving animals showed lower activity than the Lipofundin group. A similar effect was observed in catalase activity (PϽ0.05). Likewise, Lipofundin administration significantly decreased nitric oxide (NO ⅐ ) (PϽ0.05) and glutathione (GSH) (PϽ0.05) concentrations in all groups. Again, chP3R99 mAb partially preserved GSH and NO ⅐ levels. chP3 group showed NO ⅐ levels similar to those of the chP3R99 group, and no effect was observed for GSH levels. It is noteworthy that there were no differences in the effects of chP3R99 and chP3R99-LALA mAbs.
The Antiatherogenic Effect Induced by chP3R99 Immunization Was Mediated by the Generation of Anti-CS Antibodies Capable of Inhibiting LDL Binding to CS and Their Oxidation
Induction of anti-GAG antibodies in rabbit sera was tested by ELISA. An antibody response against CS and DS was detected only in chP3R99-immunized animals ( Figure 5A ; Figure VA in the online-only Data Supplement), although lower for the latter (ratios of post/pre of 6.1 and 2.38, respectively). Increases in the reactivities with heparin (ratio of post/pre, 2.87), heparan sulfate (ratio of post/pre, 2.24), and hyaluronic acid (ratio of post/pre, 3.6) were observed in sera from chP3R99-and chP3-immunized animals ( Figure  VB -VD in the online-only Data Supplement). IgG antibodies purified from chP3R99-immunized rabbits showed a similar pattern of anti-GAG reactivity to sera from this group ( Figure  5A ; Figure V in the online-only Data Supplement). These results suggested that although both chP3R99 and chP3 mAbs were able to induce antibody responses against GAGs, the antibody response against CS and DS induced by chP3R99 was the only one associated with its antiatherogenic effect.
No reactivity was detected against ECM proteins, LDL, or oxLDL either in the sera (data not shown) or in the IgG fraction purified from nonimmunized or chP3R99immunized rabbit sera ( Figure VI in the online-only Data Supplement). No human IgG was detected in chP3R99immunized rabbit sera or in the purified IgG fraction at the time of euthanization (data not shown).
We next evaluated the capacity of chP3R99-immunized rabbit sera and purified IgG to inhibit the binding of b-LDL to CS. As shown in Figure 5B , sera from chP3R99immunized rabbits (1:50) and their IgG antibody fraction (25 g/mL) were able to block LDL-CS association in 60% and 39.4%, respectively. In contrast, no inhibitory effect was observed with sera from hR3-immunized rabbits. chP3R99 mAb inhibited association by Ϸ50%, and the maximum inhibition was obtained with unlabeled LDL (73,8%). Then, we evaluated whether this quality of rabbit anti-CS antibodies had a direct implication in LDL oxidation in vitro, as demonstrated for chP3R99 mAb. Rabbit sera and purified IgG were incubated with CS followed by the addition of LDL (25 g/mL), and the effect on LDL Cu 2ϩ oxidation was evaluated by determination of MDA at 4 hours. Sera from chP3R99-immunized rabbits (1:50) and their IgG fraction (1 mg/mL) were able to inhibit MDA formation in 90% and 47%, respectively. Butylhydroxytoluene reduced the formation of MDA in 72.2% and chP3R99 mAb in 67%, and no inhibition was detected when hR3 mAb or hR3-immunized rabbit sera were used ( Figure 5C ).
Discussion
Although many factors, such as LDL oxidation, oxidative stress, endothelial dysfunction, and inflammation, are involved in atherogenesis, the retention of apoB-containing lipoproteins in the artery wall is critical in the initiation and progression of the disease. 3 Despite the cholesterol-lowering effect and anti-inflammatory properties of statins, atherosclerosis continues to progress in a significant proportion of patients, and there is no pharmaceutical treatment directly targeting the vessel wall. 12, 13 Thus, there is widespread agreement on the need of therapies directed to avoid the retention of atherogenic lipoproteins in the artery wall, which would complement current therapies. 12 In this article, we report for the first time the use of a chimeric antibody that recognizes GAGs for the treatment of atherosclerosis. chP3R99, a P3 mAb mutant in which glutamate 99 (Kabat numbering) was replaced by arginine, in-creasing the density of positive charge on H-CDR3 and consequently the affinity to their glycolipidic ligands, 26 also had a higher reactivity against GAGs than the parental chP3 antibody. On the contrary, chP3 mutants with lower arginine content as chP3S98 mAb 25 totally lost the reactivity with these antigens. Similar behavior was observed for the reactivity with human atherosclerotic plaques.
It was previously demonstrated that electrostatic interactions govern the specificity of P3 mAb, either with the carboxyl group of sialic acid or sulfated groups in sulfatides. 22, 25 In fact, the lowest reactivity of chP3R99 was with hyaluronic acid, indicating that the lack of sulfate groups affected the antibody reactivity. On the other hand, because of the high sulfate content of heparin, we expected the highest reactivity with this GAG, but in contrast, the antibody preferably reacted with CS. This observation could be explained because, unlike heparin and heparan sulfate, CS contains sulfated galactosamine residues in the disaccharide units, similar to the epitope recognized by P3 mAb in sulfatides. 22 Also, the antibody recognized human aortic PGs and decorin, which contains CS and DS as GAG side chain.
The role of arterial PGs has long been demonstrated in atherogenesis. 5, 9, 27 On interaction with intimal CSPGs, LDL particles undergo structural and functional modifications, thereby increasing their atherogenicity. 2, 28 In particular, ox-LDL induces endothelium and SMCs to express monocyte chemotactic activity and directly acts as a chemoattractant to monocytes, SMCs, and T lymphocytes. 2 Also, macrophage cell surface PGs are involved in the binding, uptake and catabolism of oxLDL, acting both as coreceptors for scavenger receptors (SR-A and CD36) and as a direct gate for oxLDL phagocytosis. 10 Although chP3R99 mAb recognized murine macrophages and inhibited the recognition of an anti-CS antibody to these cells, it did not have a direct impact on either the oxLDL binding to plasma membrane or foam Figure 5 . Antiatherogenic effects of rabbit anti-chondroitin sulfate (CS) antibodies generated on chP3R99-immunization. A, Anti-CS response in chP3R99-immunized rabbits (IR). CS-coated plates (10 g/mL) were incubated with sera from phosphate-buffered saline-, Lipofundin-, or monoclonal antibody (mAb)-receiving groups (1:3000). Also, reactivity with CS of purified non-IR IgG or chP3R99-IR IgG (25 g/mL) was evaluated. Bars represent the ratio of absorbance values from postimmune to preimmune sera, or chP3R99-IR IgG to non-IR IgG. B, Inhibition of low-density lipoprotein (LDL) binding to CS in vitro. CS-coated plates were coincubated with b-LDL (2.5 g/mL) and hR3 mAb, chP3R99 mAb, chP3R99-IR IgG, non-IR IgG (25 g/mL), or sera from chP3R99-IR and hR3-IR (1:50). Percentages of inhibition were calculated relative to LDL binding to CS in HEPES-buffered saline, sera, or purified IgG from non-IR in the same conditions. LDL was used as inhibitory control (25 g/mL). C, Inhibition of LDL oxidation in vitro. LDL oxidation was measured as nmol/L malondialdehyde (MDA) produced by preincubating CS (100 g/mL) with antibodies (1 mg/mL) or sera (1:50), followed by the addition of LDL (25 g/mL) and CuSO 4 (10 mol/L) for 4 hours. Percentages of inhibition relative to the maximum of LDL oxidation dependent on the binding to CS were calculated as described for the binding to CS. Butylhydroxytoluene was used as antioxidant control (25 mol/L). cell formation. These results are not surprising because a high number of receptors have been shown to mediate the binding and uptake of oxLDL to macrophages. In fact, interference in PGs expression either with NaClO 3 , B-D xyloxide, or glycosidases has led only to a partial decrease in oxLDL binding. 8, 10 Then, we assessed the inhibitory ability of chP3R99 mAb in the binding of LDL to CS as a potential mechanism to avoid the retention of LDL in the arterial intima. Our results showed that chP3R99 blocked Ϸ70% the binding of LDL to CS and Ϸ80% of their oxidation in vitro. Moreover, intravenously administered chP3R99 mAb accumulated in the artery wall of rats, thereby inhibiting subendothelial LDL entrapment. Consequently, there was a marked reduction of LDL oxidation in the artery wall of rats 24 hours after LDL injection, which, as demonstrated previously, 29 can be detected 6 hours after LDL administration. Hence, it is likely that this blocking property is exerted through the binding of this mAb to arterial GAGs, which could result in an antiatherogenic effect.
In fact, administration of chP3R99 mAb in low doses prevented atherosclerosis in New Zealand White rabbits. It was previously reported 30, 31 that daily infusion of Lipofundin for 8 days induces aortic lesions characterized by intima thickening and increased presence of collagen fibers. In addition, we detected the presence of large amounts of foam cells, of both macrophage and SMC origins, as well as SMC migration and transformation from contractile to synthetic phenotype, with production of abundant collagen fibers and GAGs. These characteristics, along with the presence of abundant extracellular lipid vacuoles, fibrillogenesis, and endothelial injury, demonstrated the induction of advanced lesions, resembling human type III to IV lesions. In contrast, chP3R99 mAb reduced 22-fold the intima-to-media ratio in rabbits. In these animals, either no lesions at all were observed, or only slight intimal thickening characterized by very few GAGs and collagen, resembling human type I lesions. 32 Also, the administration of Lipofundin medium-chain triglycerides/short-chain triglycerides 20% produced a significant increase in serum lipid variables in all Lipofundinreceiving groups. There is previous evidence that infusion of Lipofundin medium-chain triglycerides/short-chain triglycerides 10% fat emulsions produces an acute increase of Ϸ60% in serum total cholesterol in humans and can cause lipids and apolipoproteins to be exchanged with lipoproteins. 33 Hence, the antiatherogenic effect of chP3R99 mAb was exerted by mechanisms other than serum lipid modulation.
As mentioned, an essential step in the onset and progression of atherosclerosis is the oxidation of LDL particles, which is favored on LDL entrapment in the artery wall 7, 9 and yields a wide range of biologically active products. 34 In our study, Lipofundin-induced lesions were accompanied by disruption in prooxidant/antioxidant balance and a decrease in NO ⅐ bioavailability, as previously observed by our group. 35 Immunization with chP3R99 mAb protected the redox environment in aorta, which was consistent with the capacity of this mAb to inhibit LDL oxidation in vitro. Although most of oxidation biomarkers were affected by Lipofundin, these variables were lower in chP3R99-immunized rabbits than in animals that were treated with isotype-matched control mAbs or that received PBS before Lipofundin administration. For instance, AOPP levels were lower in this group, whereas peroxidation potential and MDA concentrations remained unaltered. High plasma concentration of MDA has long been used as a marker of oxidative stress and progression of atherosclerosis 36 and is closely associated with plaque instability and thrombotic events. 37, 38 Meanwhile, AOPPs are preferentially formed by chlorinated oxidants produced by myeloperoxidase and mediate inflammation and oxidative signaling. 39 Most of the early oxidative modifications undergone by vascular ECM-retained atherogenic lipoproteins are triggered by free radicals, especially O 2 ⅐Ϫ anion. 40 We found an increased superoxide dismutase activity on Lipofundin administration, suggesting a possible O 2 ⅐Ϫ overproduction, and consequently of catalase, to eliminate the H 2 O 2 generated. In contrast, the activity of these enzymes was significantly lower in rabbits treated with chP3R99 mAb than in groups that received control mAb or PBS before the administration of Lipofundin. It has been reported that there is an increase in vascular NADPH oxidase activity, the main source of O 2 ⅐Ϫ in the artery, 40 and also of catalase in response to H 2 O 2 and lipoperoxides produced during atherogenesis. 41 It should be noted that in most of atherosclerosis animal models induced by high-fat/high-cholesterol diets, the disease develops for several months, with the establishment of chronic inflammation. 42 However, our model is characterized by the acute induction of atherosclerosis by intravenous infusion of lipid emulsion. Thus, it is possible that the increased activity of these enzymes observed in our model could be related to homeostatic mechanisms, whereas long-term atherosclerosis models could promote a decrease in the activity of these enzymes. 43 Meanwhile, the occurrence of oxidative stress is closely related to deprivation of antioxidant defenses, such as GSH, a potent free radical scavenger. GSH is involved in the maintenance of intracellular redox environment and the regeneration of enzymes such as GSH peroxidases. 44 Administration of chP3R99 mAb preserved the levels of GSH, in line with the results discussed above. Also, the antibody protected NO ⅐ levels as indicative of endothelial function preservation. In rabbit vascular lesions, the reduced bioavailability of NO ⅐ has been attributed to inactivation of NO ⅐ rather than impairment of its synthesis. 45 NO ⅐ is an important regulator for vascular homeostasis that modulates vascular tone and inhibits SMC proliferation, platelet aggregation, and lipid peroxidation. 46 These results are consistent with those observed by transmission electron microscopy, where no endothelial damage was found in rabbits immunized with chP3R99 mAb. Modulation of oxidative stress by chP3R99 mAb is very relevant, because a number of oxidized molecules are involved in endothelial dysfunction, leukocyte recruitment and activation, and inflammation establishment. 40 In addition, immunohistochemical and ultrastructural studies showed a suppression of macrophage infiltration and foam cell formation in the aortas of rabbits treated with chP3R99. This effect has also been claimed to explain the antiathero-genic properties of human polyclonal immunoglobulins (intravenous immunoglobulins) in apoE knockout mice. Interestingly, this effect was shown to be dependent on the Fc portion of intravenous immunoglobulins, as the F(abЈ) 2 failed to ameliorate atherosclerotic lesions and to suppress macrophage accumulation in fatty streak lesions. 47 However, the possible direct antiatherogenic activity and the abrogation of macrophage infiltration induced by chP3R99 were demonstrated to be Fc independent, because in rabbits administered a chP3R99 variant with impaired Fc␥R and complement binding (chP3R99-LALA), these effects were also verified. Moreover, they were exclusive of chP3R99, as macrophages infiltrated lesions of animals treated with other isotypematched mAbs, including parental chP3, which has a lower reactivity than chP3R99 for GAGs.
The finding that chP3R99 immunization was able to induce anti-CS antibodies could be explained through the generation of an anti-idiotypic cascade, 48 in which a fraction of the induced anti-idiotypic antibodies (Ab2) behaves as a functional mimic of GAG antigenic determinants, resulting in the generation of a chP3R99 (Ab1)-like anti-anti-idiotypic (Ab3) antibody response.
Taking into account all the present results, we can propose that the mechanism(s) involved in the antiatherogenic effect produced by chP3R99 administration in rabbits could be, first, a direct inhibition of the binding of LDL to PGs of the arterial intima by chP3R99 mAb. However, we administrated very low quantities of the mAb, and human IgG was not detected in either the serum or the aorta of immunized rabbits. A second and more probable mechanism could be mediated by the anti-CS antibodies generated by immunization with chP3R99. In fact, we demonstrated not only that the anti-CS antibody response was associated with the antiatherogenic effect of chP3R99 immunization but also that the serum antibodies were capable of inhibiting LDL-CS association and their oxidation in vitro. Thus, the inhibition of subendothelial retention and oxidation of proatherogenic lipoproteins by anti-CS antibodies can prevent the oxidative stress and the macrophage inflammatory response produced by Lipofundin administration, avoiding or reducing atherosclerotic lesion development.
Although in our study, no evident toxicity was observed in the animals treated with chP3R99 mAb, additional toxicological studies are needed to address the potential risks associated with the generation of antibodies against self-antigens such as PGs, which are involved in many physiological processes. 3 In summary, our results demonstrated that immunization with chP3R99 mAb prevented the development of atherosclerosis lesions, and this effect was associated with its capacity to induce antibodies capable of blocking the binding of LDL to CS and their oxidation, thus acting as an idiotypic vaccine. In addition, our study provides data strongly supporting the response-to-retention hypothesis as the key event in the initiation of atherosclerosis.
